share_log

HC Wainwright & Co. Initiates Coverage On Finch Therapeutics Group with Buy Rating, Announces Price Target of $17

Benzinga Real-time News ·  Aug 9, 2022 06:26

HC Wainwright & Co. analyst Vernon Bernardino initiates coverage on Finch Therapeutics Group (NASDAQ:FNCH) with a Buy rating and announces Price Target of $17.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment